Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

Background: ATG-010 (selinexor) is a novel, oral selective inhibitor of nuclear export, which blocks exportin 1. US FDA has approved selinexor plus low dose dexamethasone (Sd) to treat patients (pts) with penta-refractory MM based on the STORM study. MARCH is a single arm, Phase 2, registrational st...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.4770-4770
Hauptverfasser:	Qiu, Lugui, Fu, Weijun, Xia, Zhongjun, Fu, Zhengzheng, Chen, Wenming, Chang, Chunkang, Fang, Baijun, An, Gang, Wei, Yongqiang, Cai, Zhen, Gao, Sujun, Weng, Jianyu, Chen, Lijuan, Jing, Hongmei, Fei, Li, Liu, Zhuogang, Chen, Xiequn, Liu, Jing, Yu, Yang, Wang, Aihua, Yang, Yijun, Yu, Zhinuan, Lynch, Kevin
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!